By VETTAPHARMA Reporter
U.S. pharmaceutical giant Merck & Co. is in advanced negotiations to acquire cancer-focused biotech Revolution Medicines in a landmark deal that could be valued between $28 billion and $32 billion, according to a report in the Financial Times.
Revolution Medicines, based in California, specializes in developing targeted cancer therapies aimed at blocking key gene mutations associated with hard-to-treat tumors, including pancreatic and non-small-cell lung cancers. The firm’s promising pipeline, notably its daraxonrasib candidate, has drawn significant industry attention despite its drugs not yet reaching commercial approval.
While no agreement has been finalized, the potential acquisition would mark one of the largest biotech deals in recent years, second only to Pfizer’s $43 billion purchase of Seagen. Merck’s interest underscores the strategic importance of strengthening oncology offerings as its blockbuster immunotherapy Keytruda faces looming patent expirations later this decade.
The Revolution Medicines discussions come amid broader merger and acquisition activity across the pharmaceutical sector, as companies seek innovative pipelines to offset revenue risks and fuel long-term growth. Other major firms have reportedly expressed interest, suggesting a competitive landscape that could influence deal terms and timing.
Revolution’s stock has reacted strongly to acquisition speculation, surging sharply in recent trading sessions following the acquisition news outbreak — a typical market response to takeover rumors.
#Merck #MergerAndAcquisitions #Biotechnews #CancerResearch #HealthcareBusiness #LifeSciences #Oncology #PharmaNews #PrecisionMedicine #TargetedTherapies
Source Credits
- Financial Times
Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn
Original investigative report forming the primary basis of the news story.
Source: Financial Times - Reuters
Merck in talks to buy biotech Revolution Medicines, FT reports
Secondary confirmation and amplification of the Financial Times report.
Source: Reuters - The Economic Times – Pharma
Merck in talks to buy biotech Revolution in up to $32 billion deal
Used for additional industry context and market reaction details.
Source: The Economic Times (Pharma) - Pharmaceutical Technology
Coverage on rising pharma M&A activity and biotech dealmaking trends.
Source: Pharmaceutical-Technology.com
Disclaimer: The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, and peer-reviewed articles for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. The platform and its contributors disclaim any liability for actions taken based on the information presented.
